Histone deacetylase in chronic lymphocytic leukemia

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Elevated histone deacetylase (HDAC) isoenzyme levels are observed in various cancers, including leukemias.
• HDAC inhibitors (HDACi) show therapeutic promise for carcinomas and are under active investigation.
• Understanding HDAC isoenzyme profiles in chronic lymphocytic leukemia (CLL) is crucial for optimizing HDACi treatment strategies.

Purpose of the Study:

• To quantify HDAC isoenzyme levels in patients with chronic lymphocytic leukemia (CLL).
• To compare HDAC isoenzyme levels in CLL patients with healthy controls.
• To correlate HDAC isoenzyme expression with key CLL biomarkers such as ZAP-70, CD38, and CD44.

Main Methods:

• Quantitative reverse transcriptase polymerase chain reaction (RT-qPCR) was employed to measure HDAC isoenzyme expression.
• The study included 32 patients diagnosed with CLL and 17 normal volunteer controls.
• Assays for ZAP-70, CD38, and CD44 were performed and correlated with HDAC isoenzyme levels.

Main Results:

• Significant increases in HDAC isoenzyme levels were observed across all three classes (I, II, and III) in CLL patients.
• Higher HDAC isoenzyme expression correlated with ZAP-70 positive status and CD44 expression levels.
• Specific HDAC isoenzymes found to be elevated include HDAC1, HDAC3, HDAC6, HDAC7, HDAC9, HDAC10, SIRT1, and SIRT6.

Conclusions:

• Elevated HDAC isoenzyme activity in CLL is not confined to a single class, suggesting that combination HDACi therapy targeting multiple classes may be necessary.
• Increased HDAC expression may serve as a biomarker for a poorer prognosis and more advanced disease stage in CLL.
• The correlation with ZAP-70 and CD44 suggests a link between HDAC activity and disease aggressiveness in CLL.